Chartpoppers.com releases Investment overview on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)
To find more information on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)and other big board companies, Sign up to receive updates and Investment coverage from Chartpoppers.com
(CHARTPOPPERS.COM, December 22, 2009 ) Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)
The Consolidated Investment Analysis on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) will be in particular interest to other competing companys within in its sector, such as Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co. Inc. (NYSE: MRK) and Johnson & Johnson. (NYSE: JNJ)
Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. Its research and development efforts focus on therapies for the central nervous system (with emphasis on multiple sclerosis), autoimmune diseases, and oncology. The company’s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease.
Recent News on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)
Teva Pharmaceutical Industries Ltd. said Monday it will pay $60 million to OncoGenex Pharmaceuticals Inc. under terms of a new global licensing and partnership agreement covering OncoGenex's potential cancer treatment OGX-011.
However, shares of OncoGenex tumbled on the news as investors scrutinized the terms and payment structure of the agreement.
Under the deal, OncoGenex will receive $60 million up front, including a $10 million equity investment valuing its stock at $37.38 per share, which represents a 26 percent premium to its closing price of $29.65 on Friday. The upfront payment also includes $20 million in cash and $30 million to prepay development costs.
OncoGenex also will be eligible to receive up to $370 million in milestone and other payments, along with royalties.
"The agreement provides us with capital resources for the development of OGX-011 through completion of the Phase III clinical trials and into product commercialization," said OncoGenex President and CEO Scott Cormack, in a statement.
OncoGenex, though, has to pay Isis Pharmaceuticals Inc., who co-discovered the drug with OncoGenex, $10 million upfront as part of the deal. Carlsbad, Calif.-based Isis said it also will receive 30 percent of OncoGenex's milestone and other payments, and is eligible for between 5.5 percent and 7 percent of royalties on all sales of OGX-011.
To view the Consolidated Investment Analysis on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of what’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The Consolidated Investment Analysis on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) will be in particular interest to other competing companys within in its sector, such as Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co. Inc. (NYSE: MRK) and Johnson & Johnson. (NYSE: JNJ)
Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. Its research and development efforts focus on therapies for the central nervous system (with emphasis on multiple sclerosis), autoimmune diseases, and oncology. The company’s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease.
Recent News on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)
Teva Pharmaceutical Industries Ltd. said Monday it will pay $60 million to OncoGenex Pharmaceuticals Inc. under terms of a new global licensing and partnership agreement covering OncoGenex's potential cancer treatment OGX-011.
However, shares of OncoGenex tumbled on the news as investors scrutinized the terms and payment structure of the agreement.
Under the deal, OncoGenex will receive $60 million up front, including a $10 million equity investment valuing its stock at $37.38 per share, which represents a 26 percent premium to its closing price of $29.65 on Friday. The upfront payment also includes $20 million in cash and $30 million to prepay development costs.
OncoGenex also will be eligible to receive up to $370 million in milestone and other payments, along with royalties.
"The agreement provides us with capital resources for the development of OGX-011 through completion of the Phase III clinical trials and into product commercialization," said OncoGenex President and CEO Scott Cormack, in a statement.
OncoGenex, though, has to pay Isis Pharmaceuticals Inc., who co-discovered the drug with OncoGenex, $10 million upfront as part of the deal. Carlsbad, Calif.-based Isis said it also will receive 30 percent of OncoGenex's milestone and other payments, and is eligible for between 5.5 percent and 7 percent of royalties on all sales of OGX-011.
To view the Consolidated Investment Analysis on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of what’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
CHARTPOPPERS
Paul Marek
Tel: 6047245332
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
CHARTPOPPERS
Paul Marek
Tel: 6047245332
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
